PriceTargets.com logo

DENTSPLY SIRONA - XRAY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $40.70
  • Forecasted Upside: 10.00%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$37.00 As of 01/27/2023 01:00 AM ET
▲ +0.14 (0.38%)

This chart shows the closing price for XRAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DENTSPLY SIRONA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XRAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XRAY

Analyst Price Target is $40.70
▲ +10.00% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for DENTSPLY SIRONA in the last 3 months. The average price target is $40.70, with a high forecast of $67.00 and a low forecast of $29.00. The average price target represents a 10.00% upside from the last price of $37.00.

This chart shows the closing price for XRAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 polled investment analysts is to hold stock in DENTSPLY SIRONA. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
8/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2023William BlairUpgradeUnderperform ➝ Market PerformLow
11/17/2022UBS GroupLower Target$35.00Low
11/17/2022Evercore ISIBoost Target$34.00Low
11/17/2022Robert W. BairdLower Target$32.00Low
11/16/2022The Goldman Sachs GroupLower TargetNeutral$41.00 ➝ $34.00Low
11/15/2022Barrington ResearchLower Target$51.00 ➝ $40.00Low
11/15/2022Morgan StanleyLower TargetOverweight$42.00 ➝ $39.00Low
11/14/2022Piper SandlerLower Target$38.00 ➝ $29.00Low
11/1/2022William BlairReiterated RatingUnderperformLow
10/13/2022Morgan StanleyLower TargetOverweight$44.00 ➝ $42.00Low
8/5/2022William BlairDowngradeMarket Perform ➝ UnderperformLow
7/21/2022The Goldman Sachs GroupLower TargetNeutral$42.00 ➝ $41.00Low
7/20/2022Morgan StanleyLower TargetOverweight$48.00 ➝ $44.00Low
7/11/2022Piper SandlerLower Target$41.00 ➝ $38.00N/A
6/1/2022UBS GroupUpgradeNeutral ➝ Buy$58.00 ➝ $47.00High
5/11/2022Barrington ResearchLower Target$53.00 ➝ $51.00Medium
4/22/2022HC WainwrightLower TargetHold$58.00 ➝ $48.00Medium
4/21/2022The Goldman Sachs GroupLower TargetNeutral$59.00 ➝ $47.00Medium
4/20/2022Morgan StanleyLower TargetOverweight$62.00 ➝ $52.00Low
4/20/2022Barrington ResearchLower Target$72.00 ➝ $53.00High
4/20/2022Piper SandlerReiterated RatingOverweight ➝ Neutral$71.00 ➝ $46.00Medium
4/19/2022Bank of AmericaDowngradeBuy ➝ Neutral$66.00 ➝ $49.00High
4/19/2022William BlairDowngradeOutperform ➝ Market PerformHigh
4/19/2022Robert W. BairdDowngradeOutperform ➝ Neutral$67.00 ➝ $48.00High
3/1/2022The Goldman Sachs GroupLower TargetNeutral$66.00 ➝ $59.00High
3/1/2022Barrington ResearchLower Target$79.00 ➝ $72.00High
3/1/2022Credit Suisse GroupLower TargetOutperform$68.00 ➝ $67.00High
3/1/2022HC WainwrightLower Target$66.00 ➝ $58.00Low
2/18/2022Robert W. BairdLower TargetOutperform$78.00 ➝ $67.00High
1/31/2022Morgan StanleyInitiated CoverageOverweight$62.00Low
8/9/2021HC WainwrightLower TargetNeutral$72.00 ➝ $66.00Low
8/6/2021Barrington ResearchBoost TargetOutperform$77.00 ➝ $79.00Low
5/7/2021Barrington ResearchBoost TargetOutperform$71.00 ➝ $77.00Low
5/7/2021Robert W. BairdBoost TargetOutperform$71.00 ➝ $78.00Medium
5/7/2021HC WainwrightBoost TargetNeutral$60.00 ➝ $72.00Medium
5/6/2021Piper SandlerBoost TargetOverweight$70.00 ➝ $75.00Medium
3/2/2021BarclaysBoost TargetUnderweight$50.00 ➝ $55.00Medium
3/2/2021Robert W. BairdBoost TargetOutperform$62.00 ➝ $71.00Medium
3/2/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$71.00Medium
3/2/2021HC WainwrightReiterated RatingNeutral$55.00 ➝ $60.00Low
3/1/2021Piper SandlerBoost TargetOverweight$63.00 ➝ $70.00Low
1/5/2021Robert W. BairdBoost TargetOutperform$58.00 ➝ $62.00N/A
1/5/2021BarclaysBoost TargetUnderweight$40.00 ➝ $44.00N/A
1/5/2021HC WainwrightBoost TargetNeutral$49.00 ➝ $55.00N/A
12/18/2020Stifel NicolausDowngradeBuy ➝ Hold$52.00Low
12/15/2020Piper SandlerBoost TargetOverweight$51.00 ➝ $61.00High
11/17/2020BarclaysDowngradeEqual Weight ➝ Underweight$40.00Low
11/9/2020HC WainwrightBoost TargetNeutral$45.00 ➝ $49.00High
10/22/2020GuggenheimUpgradeNeutral ➝ BuyHigh
10/5/2020JPMorgan Chase & Co.Boost TargetNeutral$45.00 ➝ $47.00Medium
8/10/2020HC WainwrightLower TargetNeutral$50.00 ➝ $45.00Low
7/20/2020Bank of AmericaBoost TargetBuy$54.00 ➝ $56.00Medium
6/16/2020Piper SandlerInitiated CoverageOverweight$51.00Low
6/15/2020HC WainwrightBoost TargetNeutral$38.00 ➝ $50.00Medium
5/27/2020Evercore ISIUpgradeIn-Line ➝ Outperform$50.00High
5/14/2020CfraLower TargetHold$53.00 ➝ $38.00High
5/11/2020BarclaysLower TargetEqual Weight$42.00 ➝ $40.00High
5/11/2020UBS GroupLower TargetNeutral$59.00 ➝ $44.00High
5/11/2020Barrington ResearchDowngradeOutperform ➝ Market PerformLow
4/24/2020HC WainwrightLower TargetNeutral$51.00 ➝ $38.00Medium
4/19/2020Credit Suisse GroupReiterated RatingBuy$50.00Low
4/19/2020Robert W. BairdUpgradeNeutral ➝ OutperformLow
4/8/2020Robert W. BairdUpgradeNeutral ➝ Outperform$57.00 ➝ $49.00Medium
4/7/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$58.00 ➝ $40.00Medium
4/2/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$66.00Low
3/17/2020JPMorgan Chase & Co.Lower TargetNeutral$65.00 ➝ $45.00High
3/13/2020Stifel NicolausLower TargetBuy$66.00 ➝ $56.00Low
3/11/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyLow
3/3/2020Barrington ResearchLower TargetOutperform$63.00 ➝ $60.00Medium
3/3/2020Robert W. BairdLower TargetNeutral$61.00 ➝ $57.00High
3/3/2020HC WainwrightReiterated RatingNeutral$60.00 ➝ $51.00High
2/19/2020Stifel NicolausBoost TargetBuy$63.00 ➝ $66.00Medium
1/19/2020BarclaysReiterated RatingHold$64.00Medium
12/11/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$65.00Low
11/15/2019HC WainwrightReiterated RatingHold$60.00Low
8/5/2019Barrington ResearchReiterated RatingBuy$63.00High
8/2/2019Wellington ShieldsUpgradeHold ➝ Gradually AccumulateHigh
7/26/2019Evercore ISIInitiated CoverageIn-line ➝ In-LineLow
7/9/2019HC WainwrightReiterated RatingNeutral ➝ Neutral$55.00 ➝ $57.00Low
5/30/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
5/6/2019Barrington ResearchUpgradeMarket Perform ➝ Outperform$63.00Medium
5/6/2019HC WainwrightReiterated RatingNeutral ➝ Neutral$49.00 ➝ $55.00Low
4/17/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$54.00High
4/5/2019HC WainwrightSet TargetHold$49.00Low
3/18/2019Bank of AmericaInitiated CoverageBuy$57.00Low
3/18/2019William BlairUpgradeMarket Perform ➝ Outperform$56.71Medium
3/12/2019UBS GroupBoost TargetNeutral ➝ Neutral$42.00 ➝ $53.00Low
3/4/2019Robert W. BairdBoost TargetNeutral ➝ Neutral$42.00 ➝ $50.00Medium
3/4/2019HC WainwrightReiterated RatingNeutral ➝ Neutral$40.00 ➝ $49.00Low
3/1/2019William BlairUpgradeMarket Perform ➝ OutperformLow
3/1/2019BarclaysSet TargetHold$49.00Low
1/17/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$42.00Low
1/6/2019BarclaysReiterated RatingHold$39.00Medium
11/9/2018Barrington ResearchReiterated RatingHoldMedium
10/19/2018The Goldman Sachs GroupUpgradeSell ➝ Buy$44.00High
8/31/2018HC WainwrightSet TargetHold$40.00Medium
8/9/2018Barrington ResearchDowngradeOutperform ➝ Market PerformLow
8/8/2018BarclaysLower TargetEqual Weight ➝ Equal Weight$55.00 ➝ $41.00Medium
8/8/2018Jefferies Financial GroupLower TargetBuy ➝ Buy$58.00 ➝ $46.00Medium
8/8/2018Stifel NicolausLower TargetBuy ➝ Buy$57.00 ➝ $46.00Medium
8/8/2018HC WainwrightReiterated RatingHold$40.00Medium
8/8/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$54.00 ➝ $40.00Medium
8/8/2018StephensDowngradeOverweight ➝ Equal Weight$75.00Medium
8/7/2018Robert W. BairdDowngradeOutperform ➝ Neutral$56.00 ➝ $38.00High
6/14/2018Morgan StanleyLower TargetOverweight ➝ Overweight$65.00 ➝ $54.00Low
6/5/2018Northcoast ResearchDowngradeBuy ➝ NeutralHigh
5/16/2018Deutsche Bank AktiengesellschaftLower TargetBuy$55.00Low
5/8/2018Robert W. BairdLower TargetOutperform ➝ Outperform$71.00High
5/8/2018Barrington ResearchLower TargetOutperform ➝ Outperform$70.00 ➝ $54.00High
5/8/2018BarclaysReiterated RatingHold$55.00High
5/8/2018Stifel NicolausReiterated RatingBuy ➝ Buy$67.00 ➝ $57.00High
5/8/2018HC WainwrightLower TargetNeutral ➝ Neutral$63.00 ➝ $52.00High
4/16/2018Jefferies Financial GroupReiterated RatingBuyLow
3/27/2018Barrington ResearchReiterated RatingBuy$69.00Medium
3/27/2018HC WainwrightSet TargetHold$63.00Medium
3/8/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$62.00Low
3/5/2018JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$75.00 ➝ $70.00Low
3/5/2018Barrington ResearchReiterated RatingOutperform ➝ Outperform$73.00 ➝ $70.00Low
3/5/2018HC WainwrightSet TargetNeutral ➝ Hold$68.00 ➝ $63.00Medium
3/2/2018Credit Suisse GroupLower TargetOutperform ➝ Outperform$73.00 ➝ $69.00High
(Data available from 1/28/2018 forward)

News Sentiment Rating

0.99 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
7/2/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/31/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2022
  • 3 very positive mentions
  • 33 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Mentions as of
11/29/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2022
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2023

Current Sentiment

  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

DENTSPLY SIRONA logo
Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Technologies and Equipment and Consumables. The Technologies and Equipment segments comprises dental technology, equipment and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers and consumable medical device products. The Consumables segment offers preventive, restorative, instruments, endodontic and orthodontic dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.
Read More

Today's Range

Now: $37.00
Low: $36.33
High: $37.22

50 Day Range

MA: $32.74
Low: $29.76
High: $37.41

52 Week Range

Now: $37.00
Low: $26.48
High: $58.70

Volume

2,128,002 shs

Average Volume

1,896,883 shs

Market Capitalization

$7.95 billion

P/E Ratio

13.81

Dividend Yield

1.36%

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of DENTSPLY SIRONA?

The following Wall Street research analysts have issued research reports on DENTSPLY SIRONA in the last twelve months: Bank of America Co., Barrington Research, Credit Suisse Group AG, Evercore ISI, HC Wainwright, Morgan Stanley, Piper Sandler, Robert W. Baird, StockNews.com, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and William Blair.
View the latest analyst ratings for XRAY.

What is the current price target for DENTSPLY SIRONA?

10 Wall Street analysts have set twelve-month price targets for DENTSPLY SIRONA in the last year. Their average twelve-month price target is $40.70, suggesting a possible upside of 10.0%. Credit Suisse Group AG has the highest price target set, predicting XRAY will reach $67.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $29.00 for DENTSPLY SIRONA in the next year.
View the latest price targets for XRAY.

What is the current consensus analyst rating for DENTSPLY SIRONA?

DENTSPLY SIRONA currently has 6 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in XRAY, but not buy more shares or sell existing shares.
View the latest ratings for XRAY.

What other companies compete with DENTSPLY SIRONA?

Other companies that are similar to DENTSPLY SIRONA include Envista, Organon & Co., Acadia Healthcare, agilon health and Globus Medical. Learn More about companies similar to DENTSPLY SIRONA.

How do I contact DENTSPLY SIRONA's investor relations team?

DENTSPLY SIRONA's physical mailing address is 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC, 28277. The medical instruments supplier's listed phone number is (844) 848-0137 and its investor relations email address is [email protected] The official website for DENTSPLY SIRONA is www.dentsplysirona.com. Learn More about contacing DENTSPLY SIRONA investor relations.